Halle Bailey and Ex DDG Reunite to Celebrate Son Halo’s First BirthdayThe NBA fined Timberwolves guard Anthony Edwards $75,000 on Monday for criticizing the referees of Saturday's game between Minnesota and the visiting Golden State Warriors . In a news release, the league said Edwards used "inappropriate and profane language" during a postgame media session after the Timberwolves' 113-103 loss. It marks the second time in two weeks that Edwards' postgame comments have cost him cash. The 23-year-old was fined $25,000 on Dec. 9 for using profane language during an interview after Minnesota won at Golden State 107-90 three days earlier. A two-time All-Star, Edwards leads the Timberwolves (14-13) with 25.6 points per game this season to go with 5.4 rebounds and four assists per contest.
In modern football, having a strong substitute bench is crucial for a team’s success. The website is packed with options for wagering on various things that happen during football matches too. The dynamics of the game have evolved significantly, with increased emphasis on 3 things: player rotation; in-game tactical changes; and managing player fitness. A well-equipped bench can often be the difference between a win and a loss, especially in high-stakes matches. If you think you know whether a team will win or lose, the 1xBet website is the perfect place to wager on what will happen with that squad. In 1st place, the substitute bench provides a vital resource for addressing unforeseen circumstances, such as injuries or underperformance during a match. A coach with a strong bench can seamlessly replace key players without compromising the team’s performance. When making you will also have the chance to wager on the impact of a substitute too. For instance, a backup number 9 with the ability to finish clinically or a substitute midfielder capable of dictating play can rescue a team trailing in a match. In 2nd place, substitutes are key to adapting tactics mid-game. There is live football betting with 1xBet, where you can also wager on teams that use different tactics. In today’s football, where strategies can shift rapidly, introducing players with different skill sets can counter the opposition’s strengths. For example, introducing a pacey winger to exploit tired defenders or deploying a defensive midfielder to protect a narrow lead can turn the tide of a match. In 3rd place there is fatigue, which must be managed. You can also to wager on teams that know how to handle this particular aspect too. Football seasons are long and grueling, with 3 kinds of competitions that pile up, which are domestic leagues, cup competitions, and international fixtures. Relying on the starting 11 for every game is neither sustainable nor effective. A strong bench allows for rotation, ensuring players remain fresh and less prone to injuries while maintaining competitive intensity across all competitions. All sorts of football tournaments will be available for wagering on the go if you use the app of the 1xBet website. Furthermore, a strong bench fosters healthy competition within the squad. Knowing that substitutes are capable of taking their spot drives starters to consistently perform at their best.
John Bolton Slams Trump Cabinet Pick Seb Gorka as a ‘Con Man’Two major automakers are joining forces to survive
( MENAFN - GlobeNewsWire - Nasdaq) . 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; . Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“NDA”) for D-PLEX100 under Fast Track and Breakthrough Therapy Designations, Previously Granted to D-PLEX100 by the FDA; . Proceeds from this Financing and Exercise of Data-Triggered Warrant Expected to Extend Cash Runway Beyond Potential NDA Approval PETACH TIKVA, Israel, Dec. 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the“Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that following the independent Data Safety Monitoring Board's (“DSMB”) review of unblinded efficacy data from the first 430 enrolled patients in the SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections (“SSIs”) in patients undergoing abdominal colorectal surgery with large incisions, the DSMB's recommendation was to conclude the study upon enrollment of 800 patients, which is the lowest sample size reassessment stop after the minimum planned number of 624 patients. At this interim analysis, the DSMB also had the option to recommend stopping SHIELD II due to futility or overwhelming efficacy or to reassess the trial's sample size to a maximum of 1,100 patients. In addition, the DSMB's confirmed the good safety profile of D-PLEX100 in SHIELD II to date. “We view the DSMB's recommendation to conclude SHIELD II upon the enrollment of 800 patients as a favorable outcome, as it is suggestive of positive efficacy signals from D-PLEX100,” said Dikla Czaczkes Akselbrad, PolyPid's Chief Executive Officer.“The sample size reassessment is an opportunity to ensure the study has sufficient power to conclusively confirm D-PLEX100's treatment benefit, and we believe this increases the trial's overall probability of success. We are now focused on completing the trial, while advancing our planned NDA and Marketing Authorization Application (“MAA”) submissions, preparing pre-launch activities, and expediting partnership discussions in and outside of the United States.” The study has enrolled 630 patients to date and enrollment of the last 170 patients is expected to occur in the first quarter of 2025. The Company anticipates reporting top-line results in the second quarter of 2025. Upon potential positive Phase 3 data, the Company expects to submit an NDA with the advantages of the Fast Track and Breakthrough Therapy designations, which were granted to D-PLEX100 in 2020. PolyPid also announced that it has entered into a securities purchase agreement for a private placement financing (the“PIPE”) led by existing institutional shareholders for $14.5 million in gross proceeds priced at $3.22 per share, the closing price on December 20, 2024. In connection with the PIPE financing, the Company has agreed to consider Yitzchak Jacobovitz, CFA, partner and lead healthcare analyst at AIGH Capital Management, for appointment to the Company's board of directors. Under the securities purchase agreement, the investors have agreed to purchase 4,493,830 of the Company's ordinary shares, no par value per share (the“Ordinary Shares”), or pre-funded warrants in lieu thereof, at a purchase price of $3.22 per share (or pre-funded warrant). The investors will also receive warrants to purchase up to 6,740,745 Ordinary Shares at an exercise price of $4.00 per share. The warrants expire upon the earlier of nine months from the date of issuance and 10 trading days following PolyPid's announcement of top-line results from its SHIELD II Phase 3 trial. Exercise of the warrants in full would result in an additional $27.0 million in gross proceeds to the Company. The PIPE is expected to close on December 26, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the sale of the securities for its ongoing SHIELD II Phase 3 clinical trial, working capital and general corporate purposes. The gross proceeds from the financing extend PolyPid's cash runway into the third quarter of 2025, beyond expected top-line results from SHIELD II. Proceeds of all warrants issued in this transaction, if exercised, would provide the Company with capital beyond NDA approval. Citizens JMP is acting as exclusive placement agent in the offering. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the“Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with the PIPE investors, the Company has agreed to file within 30 calendar days of closing one or more registration statements with the Securities and Exchange Commission (the "SEC") covering the resale of the Ordinary Shares and Ordinary Shares issuable upon exercise of the warrants and pre-funded warrants. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. About SHIELD II SHIELD II (Surgical site Hospital acquired Infection prEvention with Local D-PLEX) is a prospective, multinational, randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with standard of care (“SoC”), which includes prophylactic systemic antibiotics, compared to SoC alone arm, in the prevention of post abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The primary endpoint of the trial is measured by the proportion of subjects with either a surgical site infection (“SSI”) event as determined by a blinded and independent adjudication committee, reintervention, or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional 30 days. The trial enrolls patients in centers in the United States, Europe and Israel. About D-PLEX 100 D-PLEX100, PolyPid's lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100 received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX100 is currently in Phase 3 SHIELD II trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. About PolyPid PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn . Forward-looking Statements This press release contains“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as“expects,”“anticipates,”“intends,”“plans,”“believes,”“seeks,”“estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected timing for completion of enrollment of the SHIELD II trial, expected timing for top-line results from the SHIELD II trial, potential NDA and MAA submissions, potential clinical benefits of D-PLEX100, including safety and efficacy, pre-launch activities and partnership discussions, the gross proceeds to be received from the PIPE, intended use of proceeds from the PIPE, the anticipated closing date for the PIPE, the anticipated gross proceeds from the exercise of warrants issued in the PIPE if such warrants are exercised in full, that the gross proceeds from the financing extend the Company's cash runway into the third quarter of 2025, that proceeds of all warrants issued in this transaction, if exercised, would provide the Company with capital beyond NDA approval, and the potential addition of Mr. Jacobovitz to the Company's board of directors. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on March 6, 2024. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites. Contacts: PolyPid Ltd. Ori Warshavsky COO – US 908-858-5995 ... Investors: Brian Ritchie LifeSci Advisors 212-915-2578 ... MENAFN23122024004107003653ID1109025499 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.None
Alexander Vindman To Sue Elon Musk? Trump Impeachment Witness' Brother Hints At Defamation Lawsuit
What's the story behind the Netflix series 'Stranger Things'? Some say it was inspired by a place in New York where bizarre experiments of mind-control and time travel are rumored to have been conducted. A place featuring an elaborate system of underground tunnels where half-reptile like creatures are said to exist. Let's explore Camp Hero , an abandoned military base in Montauk, New York. Did this once secret location inspire 'Stranger Things' ? You be the judge. When the weather is warmer families and friends gather at Camp Hero State Park on Long Island to enjoy over 700 acres of nature and waterfront. Quietly tucked along side of the park's lighthouse is the decommissioned Air Force base, Camp Hero. Camp Hero was originally used for coastal defense in the 1940's and 50's during World War 2. If you have ever visited you can't help but notice the massive radar tower which some suggest was used for mind-control experiments. Officials have denied the existence of an underground network of tunnels but several individuals that used to work on the base have confirmed that they are indeed there. One former employee, Preston Nichols, published the book 'The Montauk Project; Experiments In Time' . Preston Nichols was a Radar Technician on what was called the 'Montauk Experiments' at Camp Hero. In his 1992 book, Nichols spoke of alien technology, time-travel, child abduction, UFO landing pads and much more that took place on the base. Keep scrolling to see the base that officially closed in 1994. Some say there has been scientific and military activity as recently as 2011. Secret Air Force Base In Montauk Was The Inspiration For The Netflix Show 'Stranger Things' Check out some of the other weird parallels between the fictional "Stanger Things" and the very real Camp Hero in Montauk. Inside 'Stranger Things' Creel House for Sale Take a look inside the real-life location for the "Creel House," as featured in Netflix's fourth season of Stranger Things . Gallery Credit: Lauryn Snapp Tunnel Under Niagara Falls This 115-year-old tunnel underneath the Niagara Parks Power Station is open for you to explore. See the falls in a whole new way. Gallery Credit: Karolyi
No. 15 Iowa St. 75, Middle Tennessee 59
Transport Canberra gets real time bus tracking running four weeks after launch
RedStorm's Kerns, Hamm break school record at NAIA meet